Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.
J Med Microbiol. 2023 Apr;72(4). doi: 10.1099/jmm.0.001662.
The last decade has witnessed a meteoric rise in research focused on characterizing the human microbiome and identifying associations with disease risk. The advent of sequencing technology has all but eradicated gel-based fingerprinting approaches for studying microbial ecology, while at the same time traditional microbiological culture is undergoing a renaissance. Although multiplexed high-throughput sequencing is relatively new, the discoveries leading to this are nearly 50 years old, coinciding with the inaugural Microbiology Society Fleming Prize lecture. It was an honour to give the 2022 Fleming Prize lecture and this review will cover the topics from that lecture. The focus will be on the bacterial community in early life, beginning with term infants before moving on to infants delivered prematurely. The review will discuss recent work showing how human milk oligosaccharides (HMOs), an abundant but non-nutritious component of breast milk, can modulate infant microbiome and promote the growth of spp. This has important connotations for preterm infants at risk of necrotizing enterocolitis, a devastating intestinal disease representing the leading cause of death and long-term morbidity in this population. With appropriate mechanistic studies, it may be possible to harness the power of breast milk bioactive factors and infant gut microbiome to improve short- and long-term health in infants.
过去十年见证了人们对人类微生物组进行研究并识别其与疾病风险关联的热潮。测序技术的出现几乎消除了用于研究微生物生态学的凝胶基指纹图谱方法,同时传统的微生物培养也正在复兴。尽管多重高通量测序相对较新,但导致这一技术出现的发现已有近 50 年的历史,与首届微生物学会弗莱明奖演讲同时发生。很荣幸能够发表 2022 年弗莱明奖演讲,本综述将涵盖该演讲的主题。重点将放在生命早期的细菌群落上,从足月婴儿开始,然后再讨论早产儿。本综述将讨论最近的研究工作,这些工作表明人乳寡糖(HMOs)——母乳中一种丰富但无营养价值的成分——如何调节婴儿微生物组并促进 spp 的生长。这对患有坏死性小肠结肠炎(NEC)风险的早产儿具有重要意义,NEC 是一种破坏性的肠道疾病,是该人群死亡和长期发病的主要原因。通过适当的机制研究,有可能利用母乳生物活性因子和婴儿肠道微生物组来改善婴儿的短期和长期健康。